Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Nvs crawled date : 2021 - 03 - 18 save search
Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation
Published: 2021-03-18 (Crawled : 22:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.56%
H: 0.83%
C: 0.02%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -1.05%
H: 0.86%
C: -1.4%
covid treatment results respiratory phase 3 syndros
Global Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Analysis
Published: 2021-03-18 (Crawled : 17:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.73%
H: 1.24%
C: 0.68%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.56%
H: 0.83%
C: 0.02%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.17%
H: 0.91%
C: 0.19%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.45%
H: 0.7%
C: 0.43%
covid system covid-19
Global Dermatology Drugs Market Report 2020: Market is Expected to Advance Rapidly to 2023 - Long-term Forecast to 2030
Published: 2021-03-18 (Crawled : 15:30) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.56%
H: 0.83%
C: 0.02%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.35%
H: 0.8%
C: 0.16%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.17%
H: 0.91%
C: 0.19%
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: 0.45%
H: 0.93%
C: -1.85%
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.99%
H: 0.95%
C: -0.22%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.45%
H: 0.7%
C: 0.43%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -1.54%
H: 2.76%
C: 1.63%
drug
Novartis' KISQALI (ribociclib) product monograph in Canada now includes MONALEESA-3 data demonstrating statistically significant improvement in overall survival in postmenopausal women with HR+/HER2- advanced breast cancer
Published: 2021-03-18 (Crawled : 12:30) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.56%
H: 0.83%
C: 0.02%
women cancer breast cancer her2+ her2- her2
Global Alcoholic Hepatitis Treatment Market to grow by USD 695.42 Million during 2021-2025|5.98% Year-Over-Year Growth in 2021|Technavio
Published: 2021-03-18 (Crawled : 01:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.56%
H: 0.83%
C: 0.02%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.35%
H: 0.8%
C: 0.16%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.45%
H: 0.7%
C: 0.43%
treatment hepatitis growth
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.